New vaccine combo aims to boost immune attack on bile duct cancer
NCT ID NCT06564623
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This early-stage study tests a personalized cancer vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can strengthen the body's immune response against the cancer. Participants must have already received standard chemotherapy and have a tumor with specific genetic mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SKCCC Johns Hopkins Medical Institution
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.